J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on July 1, 2007

Papers In Press, published online ahead of print March 20, 2007
J. Lipid Res., doi:10.1194/jlr.R700004-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
R700004-JLR200v1
48/7/1433    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hegele, R. A.
Right arrow Articles by Rutt, B. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hegele, R. A.
Right arrow Articles by Rutt, B. K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on March 5, 2007
Accepted on March 20, 2007

Lipodystrophies: windows on adipose biology and metabolism

Robert A. Hegele, Tisha R. Joy, Salam Al-Attar, and Brian K. Rutt

Vascular Biology, Robarts Research Institute, Schulich School of Medicine and Dentistry, London, Ontario N6A 5K8

Corresponding Author: hegele{at}robarts.ca

The lipodystrophies are characterized by loss of adipose tissue in some anatomical sites, frequently with fat accumulation in non-atrophic depots and ectopic sites such as liver and muscle. Molecularly characterized forms include Dunnigan-type familial partial lipodystrophy (FPLD), partial lipodystrophy with mandibuloacral dysplasia (MAD), Berardinelli-Seip congenital generalized lipodystrophy (CGL) and some cases with Barraquer-Simons acquired partial lipodystrophy (APL). The associated mutant gene products include: 1) nuclear lamin A in FPLD type 2 and MAD type A; 2) nuclear lamin B2 in APL; 3) nuclear hormone receptor peroxisome proliferator activated receptor gamma (PPARgamma ) in FPLD type 3; 4) the lipid biosynthetic enzyme in 1-acylglycerol-3-phosphate O-acyltransferase 2 (AGPAT2) in CGL type 1; 5) integral endoplasmic reticulum membrane protein seipin in CGL type 2; and 6) metalloproteinase ZMPSTE24 in MAD type B. An unresolved question is whether metabolic disturbances are secondary to adipose repartitioning or result from a direct effect of the mutant gene product. Careful analysis of clinical, biochemical and imaging phenotypes – using an approach called “phenomics” – reveals differences between genetically stratified subtypes that can be used to guide basic experiments and to improve understanding of common clinical entities, such as metabolic syndrome or the partial lipodystrophy syndrome associated with HIV infection (HIVPL).


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 CMAJHome page
A. Sorisky MD
A new predictor for type 2 diabetes?
Can. Med. Assoc. J., January 29, 2008; 178(3): 313 - 315.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. A. Hegele
Phenomics, Lamin A/C, and Metabolic Disease
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4566 - 4568.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.